Rachel B. Salit
Fred Hutch/University of Washington Cancer Consortium
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Rachel B. Salit as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:53 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06752694 · Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic AnemiaFred Hutchinson Cancer Center · active not recruiting · Aplastic Anemia · principal investigator
- Ph2NCT04384692 · Peritransplant Ruxolitinib for Patients With Primary and Secondary MyelofibrosisFred Hutchinson Cancer Center · active not recruiting · Primary Myelofibrosis, Secondary Myelofibrosis · principal investigator
- Ph2NCT04370301 · Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary MyelofibrosisFred Hutchinson Cancer Center · recruiting · Primary Myelofibrosis, Secondary Myelofibrosis · principal investigator
- Ph2NCT02251821 · JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary MyelofibrosisFred Hutchinson Cancer Center · completed · Primary Myelofibrosis, Secondary Myelofibrosis · principal investigator
- Ph2NCT01028716 · Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesFred Hutchinson Cancer Center · terminated · Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission, Acute Leukemia in Remission · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Center AdministrationP30CA015704 · NCI · FRED HUTCHINSON CANCER CENTER · PI WENDY LAW · fiscal years 2018 to 2026Named on NCT02251821
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:53 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis.Bone Marrow Transplant · 202039 citationsRCR 2.4
- Disability related to chronic graft -versus-host disease after alternative donor hematopoietic cell transplantation.Haematologica · 201930 citationsRCR 1.5
- Rates and Risk Factors for Post-Traumatic Stress Disorder Symptomatology among Adult Hematopoietic Cell Transplant Recipients and Their Informal Caregivers.Biol Blood Marrow Transplant · 201927 citationsRCR 1.8
- Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia.Biol Blood Marrow Transplant · 201825 citationsRCR 1.1
- Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study.Blood Adv · 202014 citationsRCR 0.8
- High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention.Blood Adv · 202410 citationsRCR 1.4